A Novel Prodrug Strategy to Treat Prostate Cancer by Targeting MYC-Driven Nucleotide Biosynthesis
Technical Report,01 Jun 2017,31 May 2019
University of California, San Francisco San Francisco United States
Pagination or Media Count:
Over the research period, the two central hypotheses were investigated thoroughly testing analogs of ribose-5-phosphate bearing radionuclides for imaging and therapy and testing a prodrug strategy for the delivery and cellular retention of these analogs into diseased prostate cancer cells. Neither could be achieved. The proposed bromine analogs were difficult to synthesize and proved unstable. The prodrug strategy did not liberate the active form necessary for cellular retention. However, through the examination of two goals, a new complimentary approach has been revealed. Furthermore, despite the difficulty with introduction of bromine atoms, fluorine was found to be easily incorporated and stabile, providing a path for the design of a traditional 18F PET imaging tracer for prostate cancer.
- Medicine and Medical Research